Tags

Type your tag names separated by a space and hit enter

Lead burden and psychiatric symptoms and the modifying influence of the delta-aminolevulinic acid dehydratase (ALAD) polymorphism: the VA Normative Aging Study.
Am J Epidemiol 2007; 166(12):1400-8AJ

Abstract

The authors evaluated the association between lead burden and psychiatric symptoms and its potential modification by a delta-aminolevulinic acid dehydratase (ALAD) polymorphism. Lead measurements in blood or bone and self-reported ratings on the Brief Symptom Inventory from 1991 to 2002 were available for 1,075 US men participating in the Department of Veterans Affairs (VA) Normative Aging Study. The authors estimated the prevalence odds ratio for the association between interquartile-range lead and abnormal symptom score, adjusting for potential confounders. An interquartile increment in tibia lead (14 microg/g) was associated with 21% higher odds of somatization (95% confidence interval of the odds ratio: 1.01, 1.46). An interquartile increment in patella lead (20 microg/g) corresponded to a 23% increase in the odds of global distress (95% confidence interval of the odds ratio: 1.02, 1.47). An interquartile increment in blood lead (2.8 microg/dl) was associated with 14% higher odds of hostility (95% confidence interval of the odds ratio: 1.02, 1.27). In all other analyses, lead was nonsignificantly associated with psychiatric symptoms. The adverse association of lead with abnormal mood scores was generally stronger among ALAD 1-1 carriers than 1-2/2-2 carriers, particularly regarding phobic anxiety symptoms (p(interaction) = 0.004). These results augment evidence of a deleterious association between lead and psychiatric symptoms.

Authors+Show Affiliations

Department of Environmental Health, Harvard School of Public Health, Boston, MA, USA. prajan@health.nyc.govNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

17823382

Citation

Rajan, Pradeep, et al. "Lead Burden and Psychiatric Symptoms and the Modifying Influence of the Delta-aminolevulinic Acid Dehydratase (ALAD) Polymorphism: the VA Normative Aging Study." American Journal of Epidemiology, vol. 166, no. 12, 2007, pp. 1400-8.
Rajan P, Kelsey KT, Schwartz JD, et al. Lead burden and psychiatric symptoms and the modifying influence of the delta-aminolevulinic acid dehydratase (ALAD) polymorphism: the VA Normative Aging Study. Am J Epidemiol. 2007;166(12):1400-8.
Rajan, P., Kelsey, K. T., Schwartz, J. D., Bellinger, D. C., Weuve, J., Sparrow, D., ... Wright, R. O. (2007). Lead burden and psychiatric symptoms and the modifying influence of the delta-aminolevulinic acid dehydratase (ALAD) polymorphism: the VA Normative Aging Study. American Journal of Epidemiology, 166(12), pp. 1400-8.
Rajan P, et al. Lead Burden and Psychiatric Symptoms and the Modifying Influence of the Delta-aminolevulinic Acid Dehydratase (ALAD) Polymorphism: the VA Normative Aging Study. Am J Epidemiol. 2007 Dec 15;166(12):1400-8. PubMed PMID: 17823382.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lead burden and psychiatric symptoms and the modifying influence of the delta-aminolevulinic acid dehydratase (ALAD) polymorphism: the VA Normative Aging Study. AU - Rajan,Pradeep, AU - Kelsey,Karl T, AU - Schwartz,Joel D, AU - Bellinger,David C, AU - Weuve,Jennifer, AU - Sparrow,David, AU - Spiro,Avron,3rd AU - Smith,Thomas J, AU - Nie,Huiling, AU - Hu,Howard, AU - Wright,Robert O, Y1 - 2007/09/06/ PY - 2007/9/8/pubmed PY - 2008/1/25/medline PY - 2007/9/8/entrez SP - 1400 EP - 8 JF - American journal of epidemiology JO - Am. J. Epidemiol. VL - 166 IS - 12 N2 - The authors evaluated the association between lead burden and psychiatric symptoms and its potential modification by a delta-aminolevulinic acid dehydratase (ALAD) polymorphism. Lead measurements in blood or bone and self-reported ratings on the Brief Symptom Inventory from 1991 to 2002 were available for 1,075 US men participating in the Department of Veterans Affairs (VA) Normative Aging Study. The authors estimated the prevalence odds ratio for the association between interquartile-range lead and abnormal symptom score, adjusting for potential confounders. An interquartile increment in tibia lead (14 microg/g) was associated with 21% higher odds of somatization (95% confidence interval of the odds ratio: 1.01, 1.46). An interquartile increment in patella lead (20 microg/g) corresponded to a 23% increase in the odds of global distress (95% confidence interval of the odds ratio: 1.02, 1.47). An interquartile increment in blood lead (2.8 microg/dl) was associated with 14% higher odds of hostility (95% confidence interval of the odds ratio: 1.02, 1.27). In all other analyses, lead was nonsignificantly associated with psychiatric symptoms. The adverse association of lead with abnormal mood scores was generally stronger among ALAD 1-1 carriers than 1-2/2-2 carriers, particularly regarding phobic anxiety symptoms (p(interaction) = 0.004). These results augment evidence of a deleterious association between lead and psychiatric symptoms. SN - 1476-6256 UR - https://www.unboundmedicine.com/medline/citation/17823382/Lead_burden_and_psychiatric_symptoms_and_the_modifying_influence_of_the_delta_aminolevulinic_acid_dehydratase__ALAD__polymorphism:_the_VA_Normative_Aging_Study_ L2 - https://academic.oup.com/aje/article-lookup/doi/10.1093/aje/kwm220 DB - PRIME DP - Unbound Medicine ER -